MedPath

Natural Frozen Embryo Transfer (FET) vs Substituted Frozen Embryo Transfer (FET)

Active, not recruiting
Conditions
Fertility Disorders
Registration Number
NCT06053827
Lead Sponsor
Clinique Ovo
Brief Summary

In frozen embryo transfer substituted cycles, patients are treated with progesterone and estrogen in an attempt to mimic the natural cycle and a transfer is planned whenever the endometrium is ready. In contrast, in frozen embryo transfer natural cycle patients are not taking any hormones, only triggered with hCG (human chorionic gonadotropin) when a dominant follicle is ready or they wait for the disappearance of the dominant follicle to plan the transfer date. Some doctors and centres shift towards using the substituted protocol in an attempt to make scheduling easier with less frequent ultrasounds.

This study will aim to compare clinical and biochemical pregnancy rates in patients who underwent frozen embryo transfers in natural cycles vs substituted cycles at the centre.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Female
Target Recruitment
500
Inclusion Criteria
  • Age < 40 years old
  • Women having undergone either a frozen embryo transfer in natural cycle or substituted cycle
  • IVF and FET cycles done at Clinique OVO
Exclusion Criteria
  • egg or embryo recipient
  • History of recurrent miscarriages, defined as ≥ 3 consecutive losses
  • Patients that needed Viagra, Plasma-Rich Platelet (PRP) or other modalities to improve their endometrial thickness
  • Uterine abnormalities
  • Abnormal hormonal profiles
  • FET Stimulated cycles
  • History of recurrent implantation failure defined as failed ≥ 2 euploid embryos transfer or ≥ 3 blastocysts

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluate the clinical pregnancy rate of embryo transfer in natural vs substituted cycles6 to 8 weeks after Frozen Embryo Transfer

clinical pregnancy is the presence of fetal heartbeat at the viability ultrasound

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Clinique Ovo

🇨🇦

Montréal, Quebec, Canada

Clinique Ovo
🇨🇦Montréal, Quebec, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.